What Are the Changes and Burden Associated With COVID-19 in Diabetes Management and Delivery of the Diabetes Services?

Coronavirus disease 2019 (COVID-19) is an ongoing pandemic that has spread to almost all countries worldwide. Diabetes mellitus (DM) has been shown to increase the risk of COVID-19 disease severity. In this review, we provide a summary of the impact of COIVD-19 on diabetes management and related services. We searched the literature using the following databases: PubMed, Medline, Scopus and Google Scholar. These databases were searched using the keywords: COVID-19, diabetes type 1 and type 2. Lockdown causing social isolation and psychological issues, showed an influence on poor glycemic control amongst people with diabetes. Hence, the use of telemedicine and various technologies in the management of diabetes has substantially increased. In individuals with COVID-19, the current practice is not in favor of using sodium-glucose cotransporter 2 (SGLT2) inhibitors. Furthermore, insulin is recommended for the management of diabetes in critically ill patients. The COVID-19 pandemic was associated with many changes in diabetes management and the delivery of diabetes services. J Endocrinol Metab. 2020;10(6):155-161 doi: https://doi.org/10.14740/jem699

[1]  D. Morris.  Managing diabetes during the COVID-19 pandemic , 2020 .

[2]  N. Rezaei,et al.  Adrenal insufficiency in coronavirus disease 2019: a case report , 2020, Journal of Medical Case Reports.

[3]  A. Scheen.  Metformin and COVID-19: From cellular mechanisms to reduced mortality , 2020, Diabetes & Metabolism.

[4]  J. Egan,et al.  SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? , 2020, Immunity & Ageing.

[5]  P. Fiorina,et al.  Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 , 2020, Acta Diabetologica.

[6]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[7]  Wajana Thaweerat.  Current evidence on pancreatic involvement in SARS-CoV-2 infection , 2020, Pancreatology.

[8]  Peter Ranscombe.  How diabetes management is adapting amid the COVID-19 pandemic , 2020, The Lancet Diabetes & Endocrinology.

[9]  D. Matthews,et al.  Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature , 2020, Diabetologia.

[10]  M. Zheng,et al.  Patients with diabetes are at higher risk for severe illness from COVID-19 , 2020, Diabetes & Metabolism.

[11]  R. Dalan.  Is DPP4 inhibition a comrade or adversary in COVID-19 infection , 2020, Diabetes Research and Clinical Practice.

[12]  Dominique Maiter,et al.  COVID-19 in diabetic patients: Related risks and specifics of management , 2020, Annales d'Endocrinologie.

[13]  S. Goyal,et al.  The Challenges of COVID-19 for People Living With Diabetes: Considerations for Digital Health , 2020, JMIR diabetes.

[14]  S. Bhadada,et al.  Reply to comment on “Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?” , 2020, Diabetes Research and Clinical Practice.

[15]  T. Danne,et al.  COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way , 2020, The Lancet Diabetes & Endocrinology.

[16]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[17]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[18]  P. Tatti,et al.  Is it fair to hope that patients with Type 1 Diabetes (autoimmune) may be spared by the infection of Covid-19? , 2020, Medical Hypotheses.

[19]  A. Ceriello.  Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory , 2020, Diabetes Research and Clinical Practice.

[20]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[21]  E. Carboni,et al.  Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? , 2020, Medical Hypotheses.

[22]  S. Cannavò,et al.  COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency? , 2020, Journal of Endocrinological Investigation.

[23]  S. Chakraborty,et al.  Diabetes self-management amid COVID-19 pandemic , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[24]  D. Mathieu,et al.  High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation , 2020, Obesity.

[25]  R. Holt,et al.  COVID‐19 and diabetes , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[26]  Akhtar Hussain,et al.  COVID-19 and diabetes: Knowledge in progress , 2020, Diabetes Research and Clinical Practice.

[27]  Jian Chen,et al.  COVID‐19 infection may cause ketosis and ketoacidosis , 2020, Diabetes, obesity & metabolism.

[28]  R. Muniyappa,et al.  COVID-19 pandemic, coronaviruses, and diabetes mellitus , 2020, American journal of physiology. Endocrinology and metabolism.

[29]  Anil Bhansali,et al.  COVID-19, diabetes mellitus and ACE2: The conundrum , 2020, Diabetes Research and Clinical Practice.

[30]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[31]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[32]  Ritesh Gupta,et al.  Clinical considerations for patients with diabetes in times of COVID-19 epidemic , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[33]  V. Jha,et al.  The Novel Coronavirus 2019 epidemic and kidneys , 2020, Kidney International.

[34]  Guillermo J. Lagos-Grisales,et al.  Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.

[35]  A. Wilder-Smith,et al.  Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak , 2020, Journal of travel medicine.

[36]  S. Asthana,et al.  Why does the NHS struggle to adopt eHealth innovations? A review of macro, meso and micro factors , 2019, BMC Health Services Research.

[37]  P. Dagnelie,et al.  Socially isolated individuals are more prone to have newly diagnosed and prevalent type 2 diabetes mellitus - the Maastricht study – , 2017, BMC Public Health.

[38]  S. Lawn,et al.  An integrative review of e-learning in the delivery of self-management support training for health professionals , 2017, BMC Medical Education.

[39]  Daniel S Johnston,et al.  Digital maturity: are we ready to use technology in the NHS? , 2017, Future Healthcare Journal.

[40]  W. Sibanda,et al.  Social support and coping in adults with type 2 diabetes , 2017, African journal of primary health care & family medicine.

[41]  Xiao-ying Zhang,et al.  Telemedicine in clinical setting , 2016, Experimental and therapeutic medicine.

[42]  David Rodbard,et al.  Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. , 2016, Diabetes technology & therapeutics.

[43]  S. Mohebi,et al.  Importance of social support in diabetes care , 2013, Journal of education and health promotion.

[44]  C. Alves,et al.  Infections in patients with diabetes mellitus: A review of pathogenesis , 2012, Indian journal of endocrinology and metabolism.

[45]  Luci K. Leykum,et al.  Association of Hypoglycemia With Mortality for Subjects Hospitalized With Pneumonia , 2010, The American journal of the medical sciences.

[46]  Jin-Kui Yang,et al.  Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes , 2009, Acta Diabetologica.

[47]  Chih-Chuan Lin,et al.  Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia , 2006, Clinical toxicology.

[48]  D. Debnath.  Activity analysis of telemedicine in the UK , 2004, Postgraduate Medical Journal.

[49]  A. Voytovich,et al.  An appraisal of goals for residency training in internal medicine. , 1985, Journal of medical education.

[50]  World Health Organization,et al.  Transmission of SARS-CoV-2: implications for infection prevention precautions , 2020 .